Valneva reports 1H results
by
Contributor since / Followers
Contributor since / Followers
1 month ago
Valneva press release (NASDAQ:VALN): 1H Revenue of €70.8M. Net Profit of €34.0 million. Operating profit
VALN
Valneva stock jumps as chikungunya vaccine wins Europe approval
by
Contributor since / Followers
Contributor since / Followers
3 months ago
designer491/iStock via Getty Images Valneva (NASDAQ:VALN) shares jumped 8.4% premarket on Monday after the vaccine
Valneva’s chikungunya vaccine wins Canada approval
by
Contributor since / Followers
Contributor since / Followers
3 months ago
designer491/iStock via Getty Images Health Canada has approved Valneva’s (NASDAQ:VALN) single-dose vaccine for the prevention
Valneva nabs EU backing for Chikungunya vaccine
by
Contributor since / Followers
Contributor since / Followers
4 months ago
designer491/iStock via Getty Images The EU drug regulator, the European Medicines Agency (EMA), announced Friday
COVID-19 vaccine makers rebound amid post-pandemic prospects
by
Contributor since / Followers
Contributor since / Followers
4 months ago
MarsBars Shares of Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), and Novavax (NASDAQ:NVAX) are continuing a
Valneva reports Q1 results
by
Contributor since / Followers
Contributor since / Followers
4 months ago
Valneva press release (NASDAQ:VALN): Q1 Revenue of €32.8M. Valneva generated a net profit of €58.9 million
CuriosityStream Inc. declares $0.025 dividend
by
Contributor since / Followers
Contributor since / Followers
6 months ago
CuriosityStream Inc. (CURI) declares $0.025/share quarterly dividend. Payable April 30; for shareholders of record April
Valneva GAAP EPS of -€0.73, revenue of €153.71M; updates FY24 guidance
by
Contributor since / Followers
Contributor since / Followers
6 months ago
Valneva press release (NASDAQ:VALN): FY GAAP EPS of -€0.73. Revenue of €153.71 million (-57.5% Y/Y).
Valneva reports FY results; initiates FY24 outlook
by
Contributor since / Followers
Contributor since / Followers
7 months ago
Valneva press release (NASDAQ:VALN): FY revenue of €153.7M (-57.5% Y/Y), including product sales of €144.6
Valneva sells chikungunya vaccine priority review voucher for $103M
by
Contributor since / Followers
Contributor since / Followers
8 months ago
designer491/iStock via Getty Images French vaccine maker Valneva (NASDAQ:VALN) said on Monday it sold the